Search results for #OncTwitter
Congratulations to Dr @MRGneuroonc on your retirement & remarkable career. Thank you for your steadfast commitment to the #braintumor field in advancing treatments for #braintumors & #survivorship/supportive care strategies for patients. #OncTwitter #survonc #supponc #btsm
Congratulations to Dr @MRGneuroonc on your retirement & remarkable career. Thank you for your steadfast commitment to the #braintumor field in advancing treatments for #braintumors & #survivorship/supportive care strategies for patients. #OncTwitter #survonc #supponc #btsm
At #GDUHem, @LipeBrea argued against the utilization of sequencing BCMA-directed therapies. Learn more: hmpgloballearningnetwork.com/site/onc/confe… #medtwitter #onctwitter #hematology
According to @NicholasShortMD, and coauthors, "the combination of mini-hyper-CVD plus venetoclax was active in heavily pretreated relapsed/refractory ALL." Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter #hematology
@EinatShacham @US_FDA @adasarimd @TargetedOnc @CathyEngMD @BijoyTelivala @RenoHemonc @GIcancerDoc @smitha42 @DrR_DUNNE @KristenCiombor @ARosen380 @Dr_M_Tejani @pashtoonkasi Completely agree! This is not a home run by any means and we absolutely need to do better. But this seems to be a step in the right direction. With Rego barely used, this gives us another potential oral option. But yes, ≥3L remains a big unmet need. #gism #crcsm #OncTwitter
Interested in mentoring the next generation of oncologists at #ASCO24? Be a situational mentor and participate in our Career Conversation meetings that connect attendees w/ more experienced oncology professionals. Sign up by 5/3: brnw.ch/21wJbkm #OncTwitter
At #GDUHem, @jmikhaelmd shared expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment. Learn more: hmpgloballearningnetwork.com/site/llm/confe… #medtwitter #onctwitter
Chronic #OcularSurfaceInflammation may be a risk factor for the development of #OcularSurfaceSquamousNeoplasia (OSSN). Published in the journal Ocular Surface. Read here: brnw.ch/21wJb7K #OcularSurface #OSSN #ChronicInflammation #OncTwitter #Ophthalmology #MedTwitter
#GISeries: Here we🗣️about the @US_FDA approval of #Fruquintinib from #FRESCO2 & how it fits in our Rx paradigm w/@adasarimd Full Int: - targetedonc.com/pivotal-practi… - oncbrothers.com/JC-FRESCO2 - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter @TargetedOnc #crcsm
Based on results from the FIREFLY-1 trial, the @US_FDA has granted accelerated approval to tovorafenib for patients 6 months and older with relapsed/refractory pediatric low-grade glioma. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter #FDAapprovals
Lung cancer can happen to anyone! Even 38 year old Stephanie, who had no risk factors! #cancer #lcsm #medtwitter #onctwitter #younglungcancer #ylci
At #GDUHem, @Ashley_Rosko1 discussed factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting. Learn more: hmpgloballearningnetwork.com/site/llm/confe… #medtwitter #onctwitter
👉Julian from Germany spent 2 years with symptoms of weight loss, flushing and diarrhea. The NET diagnosis came after visiting a third doctor. He already had metastasis to the liver. 📲Watch Julian’s story: incalliance.org/stories/julian… #LetsTalkAboutNETs #GITwitter #OncTwitter
#RenalCancer and #ThyroidCancer rates are 16% and 10% higher, respectively, in patients with #AgeRelatedMacularDegeneration (AMD). Research in the @BMJ_Ophth Read here: brnw.ch/21wJ94B #OncTwitter #NerveTumors #SkinCancer #StomachCancer #Ophthalmology #MedTwitter
As @LenAppleman, MD, PhD, and coauthors concluded, study results do not "support the use of pazopanib in patients with [metastatic renal cell carcinoma] surgically rendered [no evidence of disease]." Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter
The @US_FDA has approved lutetium Lu 177 dotatate for pediatric patients age 12 and older with SSTR-positive GEP-NETs. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter #FDAapprovals
At #GDUHem @JoshuaRichterMD discussed promising novel advances in the multiple myeloma treatment landscape, including the use of t-cell redirection therapy and possible treatment approvals to come. Learn more: hmpgloballearningnetwork.com/site/llm/confe… #medtwitter #onctwitter
👉On the #EuropeanHormoneDay, let’s put the spotlight on neuroendocrine cancer! 📢We call for HCPs to consider NETs through common symptoms with #NETInfo in 11 languages: incalliance.org/net-info-packs/ #LetsTalkAboutNETs #EndoTwitter #OncTwitter #BecauseHormonesMatter #endocrine
Join us in-person in Chicago or virtually on May 31st for "Caring for Patients With #Cancer in a Post-#COVID World: Expert Guidance on the Latest Data and Therapeutic Advances to Mitigate Infection Risk" #TwitteRx #OncTwitter #COVID19 clinicaloptions.com/events/covid-p…
Behandlungsentscheidungen für Betroffene mit NSCLC und Hirnmetastasen sollten in einem multidisziplinären Team getroffen werden, das Faktoren wie die Wirksamkeit der Immuntherapie und optimale Behandlungsabfolgen berücksichtigt. #OncTwitter ms.spr.ly/6014YDufr
